This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Lorviqua
  • /
  • A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Pa...
Clinical trial

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Read time: 1 mins
Last updated:6th Jun 2023
Status: COMPLETED
Identifier: NCT01970865
A Study Of PF-06463922 An ALK/​ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations


ClinicalTrials.gov ID: NCT01970865

Sponsor: Pfizer
Information provided by: Pfizer (Responsible Party)
Last Update Posted: 2023-06-07

Brief Summary:
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

Official Title:
PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS

Intervention / Treatment:
- Drug: PF-06463922
- Drug: Crizotinib

Category Value
Study Start (Actual)
2014-01-08
Primary Completion (Actual)
2017-03-15
Study Completion (Actual)
2023-05-24
Enrollment (Actual) 334
Study Type Interventional
Phase Phase 1
Phase 2
Other Study ID Numbers
B7461001

2013-002620-17 (EudraCT Number)


View full details